NDA 204141 · Sun Pharma Canada
Topicort
Desoximetasone · Topical · Corticosteroid
Last checked: Nov 20, 2026Latest source record: Oct 7, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Apr 11, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 0 recruiting
FAERS reports
19,273
18,360 serious, 5,296 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 8, 2025.
Desoximetasone Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older. Desoximetasone Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older ( 1 ).
Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation and protein regulation; however, the precise mechanism of action in psoriasis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 7, 2021 Supplement 9 · Efficacy LetterLabel
- Apr 11, 2013 Original approval · Type 3 - New Dosage Form LabelSummary ReviewReview
1 products under this application
- TOPICORT · DESOXIMETASONE 0.25% · SPRAY, TOPICAL · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Desoximetasone" as an intervention, any sponsor and status, largest first.
- Desoximetasone Spray 0.05%, 0.25%; Dose Ranging StudyPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01018134 · 151 participants · Start Nov 2009 · Primary completion May 2010
Drug: Desoximetasone 0.05% once daily; Desoximetasone 0.05% twice daily and 4 more · For: Psoriasis
Sites: Miami, Florida; Martinez, Georgia; Olathe, Kansas · 7 sites in all
Sun Pharmaceutical Industries, Inc.Industry
NCT02340169 · 129 participants · Start Jan 23, 2015 · Primary completion Nov 22, 2019
Drug: Topicort® (desoximetasone) Topical Spray, 0.25% · For: Plaque Psoriasis
Sites: Hawthorne, New York
- Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic DermatitisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT02595073 · 124 participants · Start Sep 4, 2015 · Primary completion Jan 17, 2017
Drug: DSXS; Placebo · For: Atopic Dermatitis
Sites: Hawthorne, New York
- Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01206387 · 120 participants · Start Aug 2010 · Primary completion Dec 2010
Drug: Desoximetasone Spray 0.25%; placebo comparator · For: Psoriasis
- Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01206660 · 120 participants · Start Aug 2010 · Primary completion Dec 2010
Drug: Desoximetasone Spray 0.25%; placebo · For: Psoriasis
Sites: Hazleton, Pennsylvania
- Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp PsoriasisPivotal-lookingStatus unknown
Siriraj HospitalAcademic, hospital or other
NCT02749656 · 105 participants (planned) · Start Jan 1, 2016 · Primary completion Jan 2018
Drug: 0.25% Desoximetasone cream (Topoxy®); 0.25% Desoximetasone cream (Topicorte®) and 1 more · For: Scalp Psoriasis
Sites: Bangkok, Thailand
Wake Forest University Health SciencesAcademic, hospital or other
NCT03050294 · 24 participants · Start Feb 1, 2017 · Primary completion Jun 1, 2017
Drug: Desoximetasone 0.25% spray · For: Atopic Dermatitis; Psoriasis
Sites: Winston-Salem, North Carolina
Sun Pharmaceutical Industries, Inc.Industry
NCT01043393 · 24 participants · Start Feb 2010 · Primary completion Jun 2010
Drug: Desoximetasone 0.25% spray · For: Psoriasis
Sites: Hot Springs, Arkansas; Albuquerque, New Mexico; Simpsonville, South Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective10,104
- pain9,142
- fatigue9,090
- rheumatoid arthritis8,445
- alopecia8,417
- systemic lupus erythematosus8,376
- pemphigus8,111
- abdominal discomfort8,037
- glossodynia7,884
- swelling7,357
- hand deformity7,164
- rash7,093
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 10 |
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 16 |
| 2010 | 19 |
| 2011 | 19 |
| 2012 | 45 |
| 2013 | 47 |
| 2014 | 64 |
| 2015 | 142 |
| 2016 | 269 |
| 2017 | 413 |
| 2018 | 520 |
| 2019 | 1,058 |
| 2020 | 2,045 |
| 2021 | 3,122 |
| 2022 | 2,964 |
| 2023 | 1,681 |
| 2024 | 3,180 |
| 2025 | 2,609 |
| 2026 | 1,027 |
Recalls
1 FDA enforcement reports for this application.
Aug 5, 2015 · Class III · Terminated
Failed Impurities/Degradation Specifications: Out of specification results for impurities testing was obtained at the 6 and 9 month time points.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical corticosteroids for treatment-resistant atopic dermatitis.
Okwundu N, Cardwell LA, Cline A, et al. · Cutis 2018 · Randomized Controlled Trial
- Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema.
Juntongjin P, Pongprasert R · Dermatol Ther 2019 · Comparative Study, Randomized Controlled Trial
- Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
Keegan BR · J Drugs Dermatol 2015 · Clinical Trial, Phase III, Randomized Controlled Trial
- Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis.
Saleem MD, Feldman SR · J Dermatolog Treat 2018 · Clinical Trial, Multicenter Study
- The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity?
Stoughton RB, Wullich K · Arch Dermatol 1989 · Clinical Trial, Randomized Controlled Trial
- Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
Borelli C, Gassmueller J, Fluhr JW, et al. · Skin Pharmacol Physiol 2008 · Comparative Study, Randomized Controlled Trial
Sponsor: Sun Pharma Canada
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.